- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01293955
Assessment of Protective Effect of JOINS on Cartilage in Knee Osteoarthritis (Joins_Carp_Ⅳ)
A Randomized, Double Blinded, Parallel Group, Placebo-controlled Clinical Trial to Assess the Protective Effect of JOINS on Cartilage in Knee Osteoarthritis
- A Pilot study
- Randomized and Double-blinded
- Placebo controlled
- In 2 parallel group (JOINS 200mg:Placebo = 1:1)
- Overall 24 months treatment (JOINS:Placebo comparison up to 12 months, Additional follow-up assessment up to 24 months)
- Provide rescue medicine throughout whole clinical trial period.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Assessment of Efficacy
Knee MRI(Magnetic resonance imaging):
- Assessment of cartilage volume, thickness in target knee
- GAG(glycosaminoglycan) concentration of target knee
- Assessment of Whole-Organ Magnetic Resonance Imaging Score (WORMS) of target knee
Knee radiography:
- Assessment of changes in minimal medial JSW(Joint Space Width) of target knee.
Knee pain(VAS)
- Assessment changes of pain in target knee.
K-WOMAC(Western Ontario and McMaster Universities Osteoarthritis Index for Korean)
- Assessment score change for pain(5 questions), stiffness(2 questions) and physical function(17 questions).
- The questionnaire is self-administered by the patients.
- Used frequency of rescue medicine.
Biochemical cartilage and bone markers
- Blood and urine sample will be collected all through the morning after a night fasting period since 10 pm the previous day to avoid the variations.
Assessment of Safety
- Adverse event
- Laboratory assessment
- Vital sign
- 12-lead ECG
- Physical examination
- Enrollment: 76
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Seoul National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
A female is eligible if she is of:
- Non-child bearing potential (i.e., physiologically incapable of becoming pregnant), including any female who is at least 2 year after post- menopausal
- Child bearing potential and agrees to the acceptable contraceptive methods used consistently and correctly
- Pregnancy test result of negative at screening
Primary Knee OA(Osteoarthritis) on medial femorotibial compartment based on ACR(American College Rheumatology) Criteria.
- ACR Criteria : With Knee pain and satisfied at least 1 of 3 (① age > 50 years, morning stiffness < 30 minute, ③ Presence of Crepitus and Osteophytes on motion)
- Appropriately signed and dated informed consent has been obtained
Exclusion Criteria:
- Rheumatoid arthritis or inflammatory arthritis.
- Bilateral total knee replacement already treated, or planning for the procedure.
- Knee prosthesis already implanted, or foreseen within the next year.
- Clinically significant hip osteoarthritis.
- Severe renal insufficiency defined as creatinine clearance < 30ml/mln(Cockcroft formula).
- Clinically significant pulmonary, hepatic, renal or heart disorder or diagnosis crucial disease by investigator ( Glycosuria(Diabetes mellitus) or asthma patients are excluded from this clinical study and the patients who has a clinically significant disease are also excluded.).
- MRI contraindications : overweight, inferior limb diameter non-fitting the knee antenna, inserted pace-maker, metallic prosthesis( if known to interfere with MRI procedure or if known to be unsafe for MRI), metallic clips, insulin pump, cytostatic pump, hearing aid, essential tremor, claustrophobia, etc,.
- Allergic reaction to Clinical trial medication.
- Other clinical trial drugs during the 1 month prior to the screening visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: JOINS 200mg
One tablet of JOINS 200mg is administered three times a day for 1 year.
The subjects who consent to participate in an extension study are treated with JOINS 200mg for another 1 year.
|
1 tablet at each time, 3 times a day
Other Names:
|
PLACEBO_COMPARATOR: Placebo
One tablet of Placebo is administered three times a day for 1 year.
The subjects who consent to participate in an extension study are treated with Placebo for another 1 year.
|
placebo of Joins 200mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Knee MRI
Time Frame: up to 4 times
|
up to 4 times
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Knee radiography
Time Frame: up to 4 times
|
up to 4 times
|
|
Knee pain(VAS)
Time Frame: up to 6 times
|
up to 6 times
|
|
K-WOMAC
Time Frame: up to 6 times
|
up to 6 times
|
|
Consumption of rescue medication
Time Frame: up to 6 times
|
The quantity of rescue medicine will be counted by investigator and recorded in official clinical research document form.
|
up to 6 times
|
Biomarker
Time Frame: up to 6 times
|
Patients will need to be strictly fasting from the night before the visit.
The data of biological cartilage and bone markers will be collected.
|
up to 6 times
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Myoungchul Lee, PH.D.., Orthopedics, Seoul National University hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Joins_Carp_IV_2009
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Knee Osteoarthritis
-
LifeBridge HealthMicroPort Orthopedics Inc.; Rubin Institute for Advanced OrthopedicsRecruitingKnee Osteoarthritis | Osteoarthritis, Knee | Knee Pain Chronic | Arthropathy of Knee Joint | Knee Disease | Osteoarthritis Knees Both | Osteoarthritis Knee Left | Osteoarthritis Knee RightUnited States
-
University Hospital, Clermont-FerrandSanofiCompletedKnee Osteoarthritis (Knee OA)France
-
Joseph E. BroylesCompletedDegenerative Lesion of Articular Cartilage of Knee | Degeneration; Articular Cartilage, Knee | Unilateral Primary Osteoarthritis of Knee | Osteoarthritis Knee
-
The Hong Kong Polytechnic UniversityCompleted
-
Federal University of São PauloCompletedKNEE OSTEOARTHRITISBrazil
-
Jiangsu XinChen-Techfields Pharma Co., LTD.Completed
-
Thammasat UniversityCompletedPrimary Knee OsteoarthritisThailand
-
Galderma R&DCompletedUnilateral Knee OsteoarthritisUnited Kingdom
-
National Yang Ming UniversityFar Eastern Memorial HospitalCompletedMedial Knee OsteoarthritisTaiwan
-
Hanlim Pharm. Co., Ltd.CompletedKnee OsteoarthritisKorea, Republic of
Clinical Trials on JOINS 200mg
-
PMG Pharm Co., LtdCompletedOsteoarthritis of the KneeKorea, Republic of
-
Jeeyoun MoonNot yet recruitingFacet Joint Syndrome
-
Dr. Chris McGlory, PhDIovate Health Sciences International IncCompleted
-
Haudongchun Co., Ltd.UnknownBacterial Vaginosis | HUDC_VT | HaudongchunKorea, Republic of
-
JW PharmaceuticalCompletedErectile DysfunctionKorea, Republic of
-
Innovent Biologics (Suzhou) Co. Ltd.Active, not recruitingAdvanced Hepatocellular CarcinomaChina
-
Chong Kun Dang PharmaceuticalCompletedHealthy VolunteersKorea, Republic of
-
SK Chemicals Co., Ltd.TerminatedAsthmaKorea, Republic of
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...Completed
-
Kwang Dong Pharmaceutical co., ltd.Unknown